Review Article| Volume 38, ISSUE 1, P161-173, March 2018

Breast Cancer in Low- and Middle-Income Countries

Why We Need Pathology Capability to Solve This Challenge
Published:December 13, 2017DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Cancer IAfRo. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocaniarcfr/Defaultaspx Accessed March 16, 2017.

        • Tefferi A.
        • Kantarjian H.
        • Rajkumar S.V.
        • et al.
        In support of a patient-driven initiative and petition to lower the high price of cancer drugs.
        Mayo Clin Proc. 2015; 90: 996-1000
        • DeSantis C.E.
        • Bray F.
        • Ferlay J.
        • et al.
        International variation in female breast cancer incidence and mortality rates.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 1495-1506
        • African Strategies for Advancing Pathology Group Members
        Quality pathology and laboratory diagnostic services are key to improving global health outcomes: improving global health outcomes is not possible without accurate disease diagnosis.
        Am J Clin Pathol. 2015; 143: 325-328
        • Nelson A.M.
        • Milner D.A.
        • Rebbeck T.R.
        • et al.
        Oncologic care and pathology resources in Africa: survey and recommendations.
        J Clin Oncol. 2016; 34: 20-26
        • Adesina A.
        • Chumba D.
        • Nelson A.M.
        • et al.
        Improvement of pathology in sub-Saharan Africa.
        Lancet Oncol. 2013; 14: e152-e157
        • Robboy S.J.
        • Weintraub S.
        • Horvath A.E.
        • et al.
        Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply.
        Arch Pathol Lab Med. 2013; 137: 1723-1732
        • Pace L.E.
        • Mpunga T.
        • Hategekimana V.
        • et al.
        Delays in breast cancer presentation and diagnosis at two rural cancer referral centers in Rwanda.
        Oncologist. 2015; 20: 780-788
        • Brinton L.
        • Figueroa J.
        • Adjei E.
        • et al.
        Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa.
        Breast Cancer Res Treat. 2017; 162: 105-114
        • Brinton L.A.
        • Awuah B.
        • Nat Clegg-Lamptey J.
        • et al.
        Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
        Int J Cancer. 2017; 140: 2667-2677
        • Adebamowo C.A.
        • Adekunle O.O.
        Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria.
        Br J Surg. 1999; 86: 665-668
        • Anyanwu S.N.
        Temporal trends in breast cancer presentation in the third world.
        J Exp Clin Cancer Res. 2008; 27: 17
        • Abdulrahman Jr., G.O.
        • Rahman G.A.
        Epidemiology of breast cancer in Europe and Africa.
        J Cancer Epidemiol. 2012; 2012: 915610
        • Othieno-Abinya N.A.
        • Nyabola L.O.
        • Abwao H.O.
        • et al.
        Postsurgical management of patients with breast cancer at Kenyatta National Hospital.
        East Afr Med J. 2002; 79: 156-162
        • Zouladeny H.
        • Dille I.
        • Wehbi N.K.
        • et al.
        Epidemiologic and clinical profiles of breast diseases in Niger.
        Int J Cancer Oncol. 2015; 2
        • Pace L.E.
        • Dusengimana J.M.V.
        • Hategekimana V.
        • et al.
        Benign and malignant breast disease at Rwanda's first public cancer referral center.
        Oncologist. 2016; 21: 571-575
        • Fisher B.
        • Redmond C.
        • Poisson R.
        • et al.
        Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.
        N Engl J Med. 1989; 320: 822-828
        • Fisher E.R.
        • Anderson S.
        • Redmond C.
        • et al.
        Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants.
        Cancer. 1993; 71: 2507-2514
        • Rosen P.P.
        • Groshen S.
        • Saigo P.E.
        • et al.
        Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.
        J Clin Oncol. 1989; 7: 1239-1251
        • Pan H.
        • Gray R.G.
        • Davies C.
        • et al.
        Long-term recurrence risks after use of endocrine therapy for only 5 years: relevance of breast tumor characteristics.
        J Clin Oncol. 2016; 34 (abstr 505)
        • Rakha E.A.
        • El-Sayed M.E.
        • Lee A.H.
        • et al.
        Prognostic significance of Nottingham histologic grade in invasive breast carcinoma.
        J Clin Oncol. 2008; 26: 3153-3158
        • Lundin J.
        • Lundin M.
        • Holli K.
        • et al.
        Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study.
        J Clin Oncol. 2001; 19: 28-36
        • Schwartz A.M.
        • Henson D.E.
        • Chen D.
        • et al.
        Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program.
        Arch Pathol Lab Med. 2014; 138: 1048-1052
        • Weigelt B.
        • Geyer F.C.
        • Reis-Filho J.S.
        Histological types of breast cancer: how special are they?.
        Mol Oncol. 2010; 4: 192-208
        • Rakha E.A.
        • Lee A.H.
        • Evans A.J.
        • et al.
        Tubular carcinoma of the breast: further evidence to support its excellent prognosis.
        J Clin Oncol. 2010; 28: 99-104
        • Caldarella A.
        • Buzzoni C.
        • Crocetti E.
        • et al.
        Invasive breast cancer: a significant correlation between histological types and molecular subgroups.
        J Cancer Res Clin Oncol. 2013; 139: 617-623
        • Dieci M.V.
        • Orvieto E.
        • Dominici M.
        • et al.
        Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.
        Oncologist. 2014; 19: 805-813
        • Howat J.M.
        • Harris M.
        • Swindell R.
        • et al.
        The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
        Br J Cancer. 1985; 51: 263-270
        • Early Breast Cancer Trialists' Collaborative Group
        Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
        Lancet. 2005; 365: 1687-1717
        • Hammond M.E.
        • Hayes D.F.
        • Dowsett M.
        • et al.
        American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
        Arch Pathol Lab Med. 2010; 134: e48-e72
        • Hammond M.E.
        • Hayes D.F.
        • Dowsett M.
        • et al.
        American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
        J Clin Oncol. 2010; 28: 2784-2795
        • Yildiz-Aktas I.Z.
        • Dabbs D.J.
        • Bhargava R.
        The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
        Mod Pathol. 2012; 25: 1098-1105
        • Pekmezci M.
        • Szpaderska A.
        • Osipo C.
        • et al.
        The effect of cold ischemia time and/or formalin fixation on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 results in breast carcinoma.
        Patholog Res Int. 2012; 2012: 947041
        • Mohsin S.K.
        Frozen section library: breast.
        Springer, New York2012
        • Dietze E.C.
        • Sistrunk C.
        • Miranda-Carboni G.
        • et al.
        Triple-negative breast cancer in African-American women: disparities versus biology.
        Nat Rev Cancer. 2015; 15: 248-254
        • Der E.M.
        • Gyasi R.K.
        • Tettey Y.
        • et al.
        Triple-negative breast cancer in Ghanaian women: the Korle Bu Teaching Hospital experience.
        Breast J. 2015; 21: 627-633
        • Proctor E.
        • Kidwell K.M.
        • Jiagge E.
        • et al.
        Characterizing breast cancer in a population with increased prevalence of triple-negative breast cancer: androgen receptor and ALDH1 expression in Ghanaian women.
        Ann Surg Oncol. 2015; 22: 3831-3835
        • Cubasch H.
        • Joffe M.
        • Hanisch R.
        • et al.
        Breast cancer characteristics and HIV among 1,092 women in Soweto, South Africa.
        Breast Cancer Res Treat. 2013; 140: 177-186
        • Rais G.
        • Raissouni S.
        • Aitelhaj M.
        • et al.
        Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
        BMC Womens Health. 2012; 12: 35
        • Eng A.
        • McCormack V.
        • dos-Santos-Silva I.
        Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.
        PLoS Med. 2014; 11: e1001720
        • Huo D.
        • Ikpatt F.
        • Khramtsov A.
        • et al.
        Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
        J Clin Oncol. 2009; 27: 4515-4521
        • McCormack V.A.
        • Joffe M.
        • van den Berg E.
        • et al.
        Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
        Breast Cancer Res. 2013; 15: R84
        • Adebamowo C.A.
        • Famooto A.
        • Ogundiran T.O.
        • et al.
        Immunohistochemical and molecular subtypes of breast cancer in Nigeria.
        Breast Cancer Res Treat. 2008; 110: 183-188
        • O’Neil D.S.
        • Keating N.L.
        • Dusengimana J.M.V.
        • et al.
        Quality of breast cancer treatment at a rural cancer center in Rwanda.
        J Glob Oncol. 2017; ([Epub ahead of print])
        • Sawe R.T.
        • Kerper M.
        • Badve S.
        • et al.
        Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration.
        BMC Cancer. 2016; 16: 204
        • Nyagol J.
        • Nyong'o A.
        • Byakika B.
        • et al.
        Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
        Anal Quant Cytol Histol. 2006; 28: 97-103
        • Sayed S.
        • Moloo Z.
        • Wasike R.
        • et al.
        Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
        Breast. 2014; 23: 591-596
        • Shulman L.N.
        • Wagner C.M.
        • Barr R.
        • et al.
        Proposing essential medicines to treat cancer: methodologies, processes, and outcomes.
        J Clin Oncol. 2016; 34: 69-75
      2. WHO to begin pilot prequalification of biosimilars for cancer treatment. Press Release 4 May 2017. Available at: http://wwwwhoint/mediacentre/news/releases/2017/pilot-prequalification-biosimilars/en/. Accessed May 17, 2017.

        • Rugo H.S.
        • Barve A.
        • Waller C.F.
        • et al.
        Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial.
        JAMA. 2017; 317: 37-47
        • Fisher B.
        • Bryant J.
        • Wolmark N.
        • et al.
        Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
        J Clin Oncol. 1998; 16: 2672-2685
        • Bear H.D.
        • Anderson S.
        • Smith R.E.
        • et al.
        Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National surgical adjuvant breast and bowel project protocol B-27.
        J Clin Oncol. 2006; 24: 2019-2027
        • Esserman L.J.
        • Berry D.A.
        • DeMichele A.
        • et al.
        Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657.
        J Clin Oncol. 2012; 30: 3242-3249
        • Symmans W.F.
        • Wei C.
        • Gould R.
        • et al.
        Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype.
        J Clin Oncol. 2017; 35: 1049-1060
        • Richards M.A.
        • Westcombe A.M.
        • Love S.B.
        • et al.
        Influence of delay on survival in patients with breast cancer: a systematic review.
        Lancet. 1999; 353: 1119-1126
        • Mpunga T.
        • Tapela N.
        • Hedt-Gauthier B.L.
        • et al.
        Diagnosis of cancer in rural Rwanda: early outcomes of a phased approach to implement anatomic pathology services in resource-limited settings.
        Am J Clin Pathol. 2014; 142: 541-545
        • Masamba L.P.L.
        • Mtonga P.E.
        • Phiri L.K.
        • et al.
        Cancer pathology turnaround time at Queen Elizabeth Central Hospital, the largest referral center in Malawi for oncology patients.
        J Glob Oncol. 2017; ([Epub ahead of print])
        • Zarbo R.J.
        • Gephardt G.N.
        • Howanitz P.J.
        Intralaboratory timeliness of surgical pathology reports. Results of two College of American Pathologists Q-Probes studies of biopsies and complex specimens.
        Arch Pathol Lab Med. 1996; 120: 234-244
        • Tannock I.F.
        10-year analysis of the ATAC trial: wrong conclusion?.
        Lancet Oncol. 2011; 12 ([author reply: 7]): 216-217
        • Goss P.E.
        • Ingle J.N.
        • Pritchard K.I.
        • et al.
        Extending aromatase-inhibitor adjuvant therapy to 10 years.
        N Engl J Med. 2016; 375: 209-219
        • Mpunga T.
        • Hedt-Gauthier B.L.
        • Tapela N.
        • et al.
        Implementation and validation of telepathology triage at cancer referral center in rural Rwanda.
        J Glob Oncol. 2016; 2: 76-82
        • Topazian H.
        • Cira M.
        • Dawsey S.M.
        • et al.
        Joining forces to overcome cancer: the Kenya cancer research and control stakeholder program.
        J Cancer Policy. 2016; 7: 36-41
        • Wu N.C.
        • Wong W.
        • Ho K.E.
        • et al.
        High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX.
        Cancer Res. 2017; 77 ([abstract: P1-03-03])
        • Berry D.A.
        • Cirrincione C.
        • Henderson I.C.
        • et al.
        Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
        JAMA. 2006; 295: 1658-1667
        • van Tienhoven G.
        • Voogd A.C.
        • Peterse J.L.
        • et al.
        Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.
        Eur J Cancer. 1999; 35: 32-38
        • Paik S.
        • Shak S.
        • Tang G.
        • et al.
        A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
        N Engl J Med. 2004; 351: 2817-2826
        • Sparano J.A.
        • Gray R.J.
        • Makower D.F.
        • et al.
        Prospective validation of a 21-gene expression assay in breast cancer.
        N Engl J Med. 2015; 373: 2005-2014
        • Albain K.S.
        • Barlow W.E.
        • Shak S.
        • et al.
        Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
        Lancet Oncol. 2010; 11: 55-65
        • Olopade O.I.
        • Pitt J.J.
        • Riester M.
        • et al.
        Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry.
        Cancer Res. 2017; 77